Eluminex Biosciences Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
65
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$9.2M
- Investors
-
10
Eluminex Biosciences General Information
Description
Developer of ophthalmic therapeutic solutions intended to focus on ophthalmology and tissue regeneration based upon recombinant human collagen and to promote the development of the industry. The company's pipeline solutions are designed to slow and lessen the effects of age and overuse on eyesight, enabling healthcare providers to better treat their patients.
Contact Information
Website
eluminexbio.comCorporate Office
- 4th Floor, Building B7, Biomedical Industrial Park
- No. 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
Corporate Office
- 4th Floor, Building B7, Biomedical Industrial Park
- No. 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
Eluminex Biosciences Timeline
Eluminex Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B1) | 20-Aug-2023 | $9.2M | Completed | Clinical Trials - Phase 3 | ||
| 2. Early Stage VC (Series B) | 14-Feb-2023 | Completed | Clinical Trials - Phase 3 | |||
| 1. Early Stage VC (Series A) | 20-Nov-2020 | $50M | $50M | Completed | Startup |
Eluminex Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Eluminex Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Eluminex Biosciences Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oriza FOFs | Fund of Funds | Minority | ||
| Suzhou Trust | Venture Capital | Minority | ||
| 3E Bioventures Capital | Venture Capital | Minority | ||
| Cenova Capital | Venture Capital | Minority | ||
| JR Capital (China) | Venture Capital | Minority |
Eluminex Biosciences Acquisitions (1)
Eluminex Biosciences’s most recent deal was a Merger/Acquisition with Retinagenix Holdings. The deal was made on 19-Jan-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Retinagenix Holdings | 19-Jan-2022 | Merger/Acquisition | Drug Discovery |
Eluminex Biosciences Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Retinagenix Holdings | Miami beach, FL |
Eluminex Biosciences FAQs
-
When was Eluminex Biosciences founded?
Eluminex Biosciences was founded in 2020.
-
Where is Eluminex Biosciences headquartered?
Eluminex Biosciences is headquartered in Suzhou, China.
-
What is the size of Eluminex Biosciences?
Eluminex Biosciences has 65 total employees.
-
What industry is Eluminex Biosciences in?
Eluminex Biosciences’s primary industry is Drug Discovery.
-
Is Eluminex Biosciences a private or public company?
Eluminex Biosciences is a Private company.
-
What is Eluminex Biosciences’s current revenue?
The current revenue for Eluminex Biosciences is .
-
How much funding has Eluminex Biosciences raised over time?
Eluminex Biosciences has raised $100M.
-
Who are Eluminex Biosciences’s investors?
Oriza FOFs, Suzhou Trust, 3E Bioventures Capital, Cenova Capital, and JR Capital (China) are 5 of 10 investors who have invested in Eluminex Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
